Skip to main content

MedPath Trial Home

Organizations News Research

Data Sources:ClinicalTrials.govEU CTRFDAEMANMPATGAHealth CanadaWHO ICTRP

MedPath Trial Home

Search trials. Track pipelines. Understand approvals. With AI-powered intelligence for clinical research.

Product

Clinical Trials
Drug Intelligence
Global Approvals
AI Research
Pricing

Resources

FAQ
Search

Company

News
About
Contact

Legal

Privacy Policy
Terms of Service

Disclaimer: This website provides information retrieval and data analysis services. The content does not constitute medical advice. Eligibility assessments are for reference only and should not replace consultation with qualified healthcare professionals. Data is sourced from public registries and regulatory agencies; MedPath does not guarantee completeness or accuracy. Always verify information with primary sources.

© 2026 MedPath Trial. All rights reserved.

We value your privacy

We use cookies to analyze site traffic and improve your experience. See our Privacy Policy.

German CLL Study Group

Home Clinical Trial Sponsors and OrganizationsGerman CLL Study Group

German CLL Study Group

ACTIVE

GermanyPrivate

Share to Twitter Share to Facebook Share to LinkedIn Share to Reddit

Clinical Trials

37

3 active

Approvals

0

Total approvals

Agencies

0

Regulatory bodies

Founded

N/A

Overview

Trial Phase Distribution

Phase

Trials

Share

Phase 2

20

54.0%

Phase 3

12

32.4%

Phase 1

3

8.1%

Trial Status Distribution

Active, not recruiting

2

5.4%

Completed

27

73.0%

Not yet recruiting

1

2.7%

Recruiting

3

8.1%

Terminated

4

10.8%

Clinical Trials

Trials sponsored by this organization (37)

A Prospective Observational Trial to Assess Treatment Sequences and Factors That Impact Overall Sur-vival in Patients With Chronic Lymphocytic Leukaemia (CLL) Treated Within First-line Studies of the GCLLSG

Not yet recruiting

Jan 20262,000 participants

A Phase-3-trial of Acalabrutinib, Obinutuzumab & Venetoclax Compared to Obinutuzumab and Venetoclax in Previously Untreated Patients With High Risk CLL

Apr 2022202 participants

Efficacy of Acalabrutinib in Very Old or Frail Patients With Treatment-naïve or Relapsed/Refractory CLL

Jun 202153 participants

Ibrutinib Monotherapy Versus Fixed-duration Venetoclax Plus Obinutuzumab Versus Fixed-duration Ibrutinib Plus Venetoclax in Patients with Previously Untreated Chronic Lymphocytic Leukaemia (CLL)

Active, not recruiting

Mar 2021897 participants

Sequential Regimen of Bendamustine Followed by Obinutuzumab (GA101), Zanubrutinib (BGB-3111) and Venetoclax (ABT-199) in Patients With Relapsed/Refractory CLL

Active, not recruiting

Oct 202042 participants

Efficacy and Safety of Zanubrutinib Plus Tislelizumab Treatment With or Without Sonrotoclax for Patients With Richter Transformation

Feb 202083 participants

Sequential Regimen of Bendamustin-Debulking Followed by Obinutuzumab, Acalabrutinib and Venetoclax in Patients with Relapsed/refractory CLL

Jan 201946 participants

Obinutuzumab Containing Conditioning Regimen for Patients With Poor Risk CLL or Richter's Transformation Requiring Allogeneic Stem Cell Transplantation

Nov 20173 participants

Page 1 of 5

Approvals

No approval data available

News

AbbVie Presents Breakthrough Data at ASH 2025 Demonstrating Significant Advances in Blood Cancer Treatment

- AbbVie unveiled compelling clinical data at ASH 2025 showcasing advances across multiple blood cancer therapeutic modalities including T-cell engagers, BCL-2 inhibitors, and antibody-drug conjugates. - The phase 3 EPCORE FL-1 trial demonstrated that epcoritamab plus rituximab and lenalidomide reduced disease progression risk by 79% in relapsed/refractory follicular lymphoma patients. - Investigational therapies etentamig and PVEK showed promising efficacy with 81% overall response rates in multiple myeloma and 63.3% complete response rates in acute myeloid leukemia, respectively.

On this page

Overview
Clinical Trials37
Approvals
News1

Back to Organizations